
Boston Scientific (BSX) Stock Forecast & Price Target
Boston Scientific (BSX) Analyst Ratings
Bulls say
Boston Scientific is supported by a diversified, high-growth portfolio that has reduced reliance on commoditized cardiac rhythm management and drug-eluting stents, while expanding into faster-growing MedTech markets through innovation and tuck-in M&A. Its 2023 revenue of $5.138B and positive Q3 operating performance underscore broad portfolio strength, with interventional cardiology, ICVTx, neuromodulation, and multiple new product launches providing several shots on goal as WATCHMAN and EP headwinds are expected to trough around 2027. The company’s healthy balance sheet, investment-grade credit, and disciplined capital allocation—along with about 36% of sales from foreign markets and an estimated ~$500M in restructuring savings—support long-term EPS growth and margin recovery.
Bears say
Boston Scientific is facing a materially weaker fundamental setup as 2026 guidance was cut to 4.25% reported revenue growth and $3.16-$3.18 in EPS, below Street expectations, while Q4 sales are now expected to decline 1-3% and EPS to fall to $0.77-$0.79. The bearish thesis is reinforced by margin compression from an unfavorable product mix, supply chain and quality investments, and the cyberattack, all of which pressure gross margin below 2025’s 70.6% and operating margin to 27.6%. Looking beyond 2026, management’s more cautious 2027 view, delays to FarawaveUltra and Faraflex, and ongoing share loss in EP and Watchman suggest growth and earnings could remain challenged well into 2028.
This aggregate rating is based on analysts' research of Boston Scientific and is not a guaranteed prediction by Public.com or investment advice.
Boston Scientific (BSX) Analyst Forecast & Price Prediction
Start investing in Boston Scientific (BSX)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Boston Scientific (BSX) Forecast
Boston Scientific (BSX) Analyst Forecast & Price Prediction
Start investing in Boston Scientific (BSX)
Order type
Buy in
Order amount
Est. shares
0 shares